Tirzepatide GLN19 (Q19) Deamidation Impurity Reference Standard Antibodies (G-L) Swissprot No Q96PE1 Gene Accession

Swissprot No Q96PE1 Gene Accession NP_116166 WB Predicted band size 143 kDa WB Positive control WB Recommended dilution 500-2000 IHC predicted cell location Predicted cell location: Cell membrane IHC positive control Positive control: Human liver cancer IHC Recommed dilution Recommended dilution: 50-200 Storage

TAE and TBE have different conductive properties

Many mutations in this gene are known in man

Defects in this gene are the cause of aromatic L-amino-acid decarboxylase deficiency (AADCD)

shentek-subtitle { color: #2d3748

Tirzepatide GLN19 (Q19) Deamidation Impurity Reference Standard Antibodies (G-L) Swissprot No Q96PE1 Gene AccessionDescription Tirzepatide GLN19 deamidation impurity is a high purity impurity reference standard used for impurity profiling, analytical method development, and quality control of Tirzepatide. Deamidation at glutamine residue 19 is a well characterized degradation pathway in peptide drug substances that can be monitored by HPLC and LC MS. This reference standard supports accurate detection and quantification of deamidated species, ensuring product